| Name | Title | Contact Details |
|---|
Vinfen Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Timber PT Management is a company that offers revenue cycle management services to private physical therapy groups seeking to expand their practices.
Nevada Health Centers, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Nevada Health Centers, Inc. is based in Carson City, NV. You can find more information on Nevada Health Centers, Inc. at www.nvrhc.org
Maryland Health Benefit Exchange’s (MHBE) resource site for stakeholders. We continue to work toward the opening of the marketplace in October 2013 of Maryland Health Connection, the state-based health insurance exchange where Maryland residents and small businesses will be able to explore and compare health insurance plans, qualify for cost-sharing reductions and tax credits and complete the enrollment process. The information available through this site supports our work with stakeholders. Meeting schedules and materials, career information, and procurement details are routinely posted. Additionally, the site serves as a resource for the many advisory committees and programs in progress and in development as we collectively work together to establish a health insurance marketplace that best meets the needs of all Marylanders.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."